Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype-Guided FOLFIRABRAX in Advanced GI Malignancies
NCT02333188Phase 1Completed
- Sponsor
- University of Chicago
- Start
- Dec 2014
- Primary completion
- Dec 2017
- Modality
- Polymer-based Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nab-paclitaxel and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in pancreatic adenocarcinoma (PDAC), gastric adenocarcinoma, cholangiocarcinoma (CCA) and 3 more, sponsored by University of Chicago. Primary endpoint: Dose-Limiting Toxicity Rate at 4 weeks. Started Dec 2014; status: completed.
02
Drugs
nab-paclitaxelirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
pancreatic adenocarcinoma (PDAC)gastric adenocarcinomacholangiocarcinoma (CCA)gallbladder adenocarcinomaampullary carcinoma
Beyond the preview
Go deeper on NCT02333188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02333188.